.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Argus Health
Julphar
Dow
Mallinckrodt
UBS
Baxter
US Department of Justice
Merck
McKinsey

Generated: June 25, 2017

DrugPatentWatch Database Preview

ADEMPAS Drug Profile

« Back to Dashboard

What is the patent landscape for Adempas, and what generic Adempas alternatives are available?

Adempas is a drug marketed by Bayer Hlthcare and is included in one NDA. There are two patents protecting this drug.

This drug has seventy-five patent family members in forty-three countries.

The generic ingredient in ADEMPAS is riociguat. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the riociguat profile page.

Summary for Tradename: ADEMPAS

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list42
Clinical Trials: see list7
Patent Applications: see list60
Drug Prices:see details
DailyMed Link:ADEMPAS at DailyMed

Pharmacology for Tradename: ADEMPAS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare
ADEMPAS
riociguat
TABLET;ORAL204819-001Oct 8, 2013RXYesNo6,743,798► SubscribeYY ► Subscribe
Bayer Hlthcare
ADEMPAS
riociguat
TABLET;ORAL204819-005Oct 8, 2013RXYesYes7,173,037► SubscribeYY ► Subscribe
Bayer Hlthcare
ADEMPAS
riociguat
TABLET;ORAL204819-002Oct 8, 2013RXYesNo► Subscribe► Subscribe
Bayer Hlthcare
ADEMPAS
riociguat
TABLET;ORAL204819-001Oct 8, 2013RXYesNo► Subscribe► Subscribe
Bayer Hlthcare
ADEMPAS
riociguat
TABLET;ORAL204819-003Oct 8, 2013RXYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ADEMPAS

Country Document Number Estimated Expiration
Netherlands300659► Subscribe
Israel140584► Subscribe
Cuba23453► Subscribe
Poland214985► Subscribe
Malaysia133392► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ADEMPAS

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
14/028Ireland► SubscribePRODUCT NAME: RIOCIGUAT OR A SALT, ISOMER OR HYDRATE THEREOF; REGISTRATION NO/DATE: EU/1/13/907/001-015 20140327
90030-2Sweden► SubscribePRODUCT NAME: RIOCIGUAT OCH SALTER, ISOMERER OCH HYDRATER DAERAV; REG. NO/DATE: EU/1/13/907 20140327
C0032France► SubscribePRODUCT NAME: RIOCIGUAT,SES SELS,SES ISOMERES ET SES HYDRATES.; REGISTRATION NO/DATE: EU/1/13/907/001-015 20140327
0659Netherlands► SubscribePRODUCT NAME: RIOCIGUAT, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF HYDRAAT; REGISTRATION NO/DATE: EU/1/13/907 20140331
400019Hungary► SubscribePRODUCT NAME: RIOCIGUAT; REG. NO/DATE: EU/1/13/97 20140327
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Deloitte
Citi
Daiichi Sankyo
Chubb
Accenture
Argus Health
Healthtrust
QuintilesIMS
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot